Please login to the form below
Healthcare Glossary
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W |
Opportunity cost
The value given up by choosing one business, service or product, expenditure over another. It is the abnegation associated to the second best choice available to someone, or group, who has chosen among numerous similarly exclusive choices.
See also:
Customer loyalty
Brand value
Related terms
Attitude Awareness Usage Study (AAU), Launch, Reimbursement, Life cycle (product), Channel marketing, Attitudinal scaling, Decline Stage, Customer lifetime value (CLV), Normal distribution, Internal marketing, Product differentiation, Economic regulation, Confidence level, Crisis management, Business to consumer (B2C),
Subscribe to our email news alerts
Featured jobs
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Europe’s cancer community publishes new report on transforming patient care
- Eli Lilly announces $450m investment in US manufacturing site
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- ASH 2022: bad blood but big advances
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- MIT researchers develop AI model to detect future lung cancer risk
- The challenges of identifying rare diseases
- Live Webinar: Streamlining Healthcare Delivery Through Digital Care Journeys
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- Boehringer reports positive phase 2 data for spesolimab in generalised pustular psoriasis
- Microfoundations matter
- 5 ways we’re enhancing our services to support our clients in 2023
- EU outlines measures to mitigate antibiotic shortage across Europe
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- Europe’s cancer community publishes new report on transforming patient care
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- Boehringer reports positive phase 2 data for spesolimab in generalised pustular psoriasis
- EC launches cancer imaging initiative to accelerate innovation and early diagnosis
PMHub
Wilmington Healthcare
A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...
